A novel tumor-specific broad-spectral monoclonal antibody to PL2L60 is highly effective for the treatment of various types of cancers from human and mouse.

There are numerous antibodies used for cancer therapy in clinic, but they are essentially less efficacy than expected. None of them has tumor-specific and broad-spectral properties. PIWIL2-like (PL2L) protein 60 (PL2L60) is a product of alienated activation of PIWIL2 gene, and has been found to be specifically and widely expressed in various types of cancers, including hematopoietic and solid ones. Current study aims to investigate whether a monoclonal antibody (mAb) to PL2L60 has both tumor-specific and broad-spectral properties, which can be used universally to treat various types of cancers. The expression of PL2L60 protein in the cell surface and cytoplasm were determined in a panel of human and mouse tumor cell lines by flow cytometry, immunofluorescent microscopy and Western Blotting. The apoptosis and the cell cycle arrest of the tumor cells treated with mAb KAO3 were evaluated by flow cytometry. The tumorigenesis of the mAb KAO3-pretreated tumor cells was determined by tumor incidence and tumor size, and the efficacy of mAb KAO3 treatment on tumor growth in tumors-bearing mice were kinetically evaluated. Complement-dependent cytotoxicity (CDC) assay was used to determine the capacity of mAb KAO3 to kill tumor cells. Treatment of human or mouse tumor cells from hematopoietic or solid tumors with mAb KAO3 at the time of inoculation efficiently inhibited tumorigenesis in the severe combined immunodeficient (SCID) mice. Moreover, injection of mAb KAO3 into established tumors significantly inhibited their growth, and prolonged survival of the tumor-bearing mice, including lymphoma, breast cancer, lung cancer and cervical cancer. The efficacy of mAb KAO3 treatment is likely associated with its binding to PL2L60 expressed on tumor cell surface, which may lead to cancer cell death through blocking cell cycling and/or activation of complement. In conclusion, we have identified a tumor-specific mAb to PL2L60 (KAO3), which may be used potentially to treat all the types of human cancers including from both hematopoietic and solid ones.

[1]  Hailong Wu,et al.  An unusual intragenic promoter of PIWIL2 contributes to aberrant activation of oncogenic PL2L60 , 2017, Oncotarget.

[2]  B. Savoldo,et al.  Chimeric antigen receptor-redirected T cells return to the bench. , 2016, Seminars in immunology.

[3]  S. Forman,et al.  Smart CARs engineered for cancer immunotherapy , 2015, Current opinion in oncology.

[4]  A. Ribas,et al.  The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? , 2015, Current opinion in immunology.

[5]  N. Bhardwaj,et al.  Cancer immunotherapy: Dendritic-cell vaccines on the move , 2015, Nature.

[6]  I. Gainetdinov,et al.  Expression Profiles of PIWIL2 Short Isoforms Differ in Testicular Germ Cell Tumors of Various Differentiation Subtypes , 2014, PloS one.

[7]  Hl Wu,et al.  PIWIL2 (piwi-like RNA-mediated gene silencing 2) , 2014 .

[8]  Y. Liu,et al.  A TALEN‐based specific transcript knock‐down of PIWIL2 suppresses cell growth in HepG2 tumor cell , 2014, Cell proliferation.

[9]  Huaqin Sun,et al.  Piwil2 Inhibits Keratin 8 Degradation through Promoting p38-Induced Phosphorylation To Resist Fas-Mediated Apoptosis , 2014, Molecular and Cellular Biology.

[10]  Xulei Zheng,et al.  PIWIL2 induces c-Myc expression by interacting with NME2 and regulates c-Myc-mediated tumor cell proliferation , 2014, Oncotarget.

[11]  Hailong Wu,et al.  PIWIL 2 ( piwi-like RNA-mediated gene silencing 2 ) , 2014 .

[12]  Charles G. Drake,et al.  Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer , 2014, Nature Reviews Clinical Oncology.

[13]  Yanfeng Gao,et al.  The immunogenicity of a novel cytotoxic T lymphocyte epitope from tumor antigen PL2L60 could be enhanced by 4-chlorophenylalanine substitution at position 1 , 2013, Cancer Immunology, Immunotherapy.

[14]  R. Shirkoohi,et al.  Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern , 2013, Medical Oncology.

[15]  Dawei Li,et al.  Piwil2 modulates the proliferation and metastasis of colon cancer via regulation of matrix metallopeptidase 9 transcriptional activity , 2012, Experimental biology and medicine.

[16]  H. Chang,et al.  Clinicopathologic Implications of PIWIL2 Expression in Colorectal Cancer , 2012, Korean journal of pathology.

[17]  Yi-lu Lu,et al.  Piwil2 Suppresses P53 by Inducing Phosphorylation of Signal Transducer and Activator of Transcription 3 in Tumor Cells , 2012, PloS one.

[18]  Xiaoying Shen,et al.  The PIWI protein acts as a predictive marker for human gastric cancer. , 2012, International journal of clinical and experimental pathology.

[19]  A. Wani,et al.  Germline Stem Cell Gene PIWIL2 Mediates DNA Repair through Relaxation of Chromatin , 2011, PloS one.

[20]  Qi-En Wang,et al.  Stem cell protein Piwil2 modulates chromatin modifications upon cisplatin treatment. , 2011, Mutation research.

[21]  C. Shapiro,et al.  Identification of Piwil2-Like (PL2L) Proteins that Promote Tumorigenesis , 2010, PloS one.

[22]  J. Hengstler,et al.  Pathways of proliferation and antiapoptosis driven in breast cancer stem cells by stem cell protein piwil2. , 2010, Cancer research.

[23]  S. Barsky,et al.  Piwil2 expressed in various stages of cervical neoplasia is a potential complementary marker for p16. , 2010, American journal of translational research.

[24]  C. Shapiro,et al.  Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. , 2010, International journal of clinical and experimental pathology.

[25]  Chaohui Yu,et al.  Argonaute proteins: potential biomarkers for human colon cancer , 2010, BMC Cancer.

[26]  T. Nakano,et al.  MILI, a PIWI-interacting RNA-binding Protein, Is Required for Germ Line Stem Cell Self-renewal and Appears to Positively Regulate Translation* , 2009, Journal of Biological Chemistry.

[27]  Jian-xin Gao,et al.  Epigenetic progenitors in tumor initiation and development , 2009 .

[28]  S. Barsky,et al.  Precancerous Stem Cells Can Serve As Tumor Vasculogenic Progenitors , 2008, PloS one.

[29]  N. Heerema,et al.  Precancerous Stem Cells Have the Potential for both Benign and Malignant Differentiation , 2006, PloS one.

[30]  H. Radzun,et al.  Stem-cell protein Piwil2 is widely expressed in tumors and inhibits apoptosis through activation of Stat3/Bcl-XL pathway. , 2006, Human molecular genetics.

[31]  Yoichi Matsuda,et al.  Mili, a mammalian member of piwi family gene, is essential for spermatogenesis , 2004, Development.

[32]  Shinsei Minoshima,et al.  Identification of eight members of the Argonaute family in the human genome. , 2003, Genomics.

[33]  Y. Matsuda,et al.  Two mouse piwi-related genes: miwi and mili , 2001, Mechanisms of Development.

[34]  A. Spradling,et al.  A novel group of pumilio mutations affects the asymmetric division of germline stem cells in the Drosophila ovary. , 1997, Development.